Your browser's JavaScript is disabled.

To properly view the content on this page, please enable JavaScript.

Publications

Filter by:

Featured

Imetelstat Achieved Prolonged, Continuous Transfusion Independence in Patients With Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory to Erythropoiesis Stimulating Agents Within the IMerge Phase 2 Study

Clinical Imetelstat: MDS Imetelstat

ASH 2022

Platzbecker, et al.

Imetelstat-Mediated Alterations in Lipid Metabolism to Induce Ferroptosis As Therapeutic Strategy for Acute Myeloid Leukemia

Imetelstat Non-clinical Imetelstat

ASH 2022

Bruedigam C, et al.

All

MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor

Clinical Imetelstat: MF Imetelstat

ASH 2022

Mascarenhas, et al.

An Open Label, Dose Escalation and Expansion, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Intermediate-1, Intermediate-2 or High-Risk Myelofibrosis

Clinical Imetelstat: MF Imetelstat

ASH 2022

Bradley T, et al.

Imetelstat Achieved Prolonged, Continuous Transfusion Independence in Patients With Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory to Erythropoiesis Stimulating Agents Within the IMerge Phase 2 Study

Clinical Imetelstat: MDS Imetelstat

ASH 2022

Platzbecker, et al.

Imetelstat-Mediated Alterations in Lipid Metabolism to Induce Ferroptosis As Therapeutic Strategy for Acute Myeloid Leukemia

Imetelstat Non-clinical Imetelstat

ASH 2022

Bruedigam C, et al.

Pharmacological Inhibitory Effect of Imetelstat, A Novel Human Telomerase Inhibitor in Diffuse Large B-cell Lymphoma and Peripheral T-Cell Lymphoma

Imetelstat Non-clinical Imetelstat

Blood 2022

Aradhya A, et al.

Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design

Clinical Imetelstat: MF Imetelstat

Future Oncology 2022

Mascarenhas, et al.

Imetelstat Induces Leukemia Stem Cell Death in Pediatric Acute Myeloid Leukemia Patient-Derived Xenografts

Imetelstat Non-clinical Imetelstat

Journal of Clinical Medicine 2022

Barwe, et al.

The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes

Relevant MF Publications

Cancer 2022

Mascarenhas, et al.

Clinical and biological characterization of Low Risk MDS patients according to Ring Sideroblasts (RS). Comparison between the 3 subgroups in WHO2017 classification. Study from the Spanish MDS registry

Relevant MDS Publications

ASH 2021

Cadenas FL, et al.

Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data

Clinical Imetelstat: MF Imetelstat

Annals of Hematology 2021

Kuykendall, et al.

Efficacy of Imetelstat is Independent of Molecular Subtypes in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESA)

Clinical Imetelstat: MDS Imetelstat

EHA 2021

Platzbecker, et al.

Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis

Clinical Imetelstat: MF Imetelstat

Journal of Clinical Oncology 2021

Mascarenhas, et al.

Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study

Clinical Imetelstat: MDS Imetelstat

Journal of Clinical Oncology 2020

Steensma, et al.

Imetelstat Demonstrates an Acceptable Safety Profile in Myeloid Malignancies

Clinical Imetelstat: MDS Imetelstat

EHA 2021

Mascarenhas, et al.

Current challenges and unmet needs in myelodysplastic syndromes

Relevant MDS Publications

Leukemia 2021

Platzbecker, et al.

Patients

We are on a mission to improve and extend lives

Discover more about our commitment to patients

Learn more